Effects of subcutaneous recombinant IL-2 on humoral immunity in advanced cancer patients

A. Casamassima, M. Guida, A. Latorre, I. Abbate, V. Triantafillou, M. Musci, M. De Lena

Research output: Contribution to journalArticlepeer-review


Immunotherapy represents a promising biological approach to cancer treatment. Important haemato-immunological modifications during rIL-2 treatment have been demonstrated in all patients treated, independently of the schedule and mode of rIL-2 administration. Generally, there is a lack of correlation between treatment-related modifications and clinical response. rIL-2 cell-mediated responses have been extensively studied but the role of humoral immunity is still unclear. We evaluated the peripheral blood CD4, CD8, CD19 and CD25 lymphocyte subset modifications and serum levels of immunoglobulin, IL-6 and IL-2 in 19 patients with malignant melanoma and renal cell carcinoma undergoing subcutaneous administration of IL-2. Our results suggest that humoral immunity is only marginally involved; however, the parameter variations observed suggest that further studies are necessary.

Original languageEnglish
Pages (from-to)171-176
Number of pages6
JournalInternational Journal of Oncology
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Effects of subcutaneous recombinant IL-2 on humoral immunity in advanced cancer patients'. Together they form a unique fingerprint.

Cite this